JP2023521030A5 - - Google Patents

Info

Publication number
JP2023521030A5
JP2023521030A5 JP2022560218A JP2022560218A JP2023521030A5 JP 2023521030 A5 JP2023521030 A5 JP 2023521030A5 JP 2022560218 A JP2022560218 A JP 2022560218A JP 2022560218 A JP2022560218 A JP 2022560218A JP 2023521030 A5 JP2023521030 A5 JP 2023521030A5
Authority
JP
Japan
Prior art keywords
composition according
ibudilast
pharmaceutically acceptable
acceptable salt
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022560218A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023521030A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/025732 external-priority patent/WO2021207054A1/en
Publication of JP2023521030A publication Critical patent/JP2023521030A/ja
Publication of JP2023521030A5 publication Critical patent/JP2023521030A5/ja
Pending legal-status Critical Current

Links

JP2022560218A 2020-04-06 2021-04-05 イブジラストを用いる、患者におけるマクロファージ遊走性阻止因子の血漿レベルの減少方法 Pending JP2023521030A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063005792P 2020-04-06 2020-04-06
US63/005,792 2020-04-06
PCT/US2021/025732 WO2021207054A1 (en) 2020-04-06 2021-04-05 Methods of reducing plasma level of macrophage migratory inhibitory factor in patients with ibudilast

Publications (2)

Publication Number Publication Date
JP2023521030A JP2023521030A (ja) 2023-05-23
JP2023521030A5 true JP2023521030A5 (cg-RX-API-DMAC7.html) 2024-04-15

Family

ID=75674991

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022560218A Pending JP2023521030A (ja) 2020-04-06 2021-04-05 イブジラストを用いる、患者におけるマクロファージ遊走性阻止因子の血漿レベルの減少方法

Country Status (6)

Country Link
US (2) US12213966B2 (cg-RX-API-DMAC7.html)
EP (1) EP4132521A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023521030A (cg-RX-API-DMAC7.html)
CN (1) CN115335049A (cg-RX-API-DMAC7.html)
CA (1) CA3174413A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021207054A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2745814C1 (ru) * 2020-06-05 2021-04-01 Закрытое Акционерное Общество "Биокад" Водная фармацевтическая композиция левилимаба и ее применение
JP2024528731A (ja) 2021-07-26 2024-07-30 メディシノバ・インコーポレイテッド 眼癌転移を予防するためのイブジラスト
US12042485B2 (en) 2021-10-07 2024-07-23 Medicinova, Inc. Methods of minimizing cancer metastasis
JP2025504984A (ja) 2022-02-01 2025-02-19 メディシノバ・インコーポレイテッド Covid後症状の治療における使用のためのイブジラスト
US20240016729A1 (en) * 2022-07-13 2024-01-18 Medicinova, Inc. Injectable formulations of ibudilast

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8562198A (en) 1998-08-10 2000-03-06 Kyorin Pharmaceutical Co. Ltd. Remedies for multiple sclerosis
JP2007512337A (ja) * 2003-11-21 2007-05-17 コンビナトアールエックス インコーポレーティッド 炎症性障害の治療のための方法および試薬
WO2006063048A2 (en) 2004-12-06 2006-06-15 Avigen, Inc. Ibudilast for treating neuropathic pain and associated syndromes
EP2026804A1 (en) * 2006-05-31 2009-02-25 Avigen, Inc. Ibudilast for inhibiting macrophage migration inhibitory factor (mif) activity
CA2693697C (en) * 2007-07-11 2017-07-25 Medicinova, Inc. Treatment of progressive neurodegenerative disease with ibudilast
US20110028510A1 (en) * 2009-02-18 2011-02-03 Combinatorx (Singapore) Pte. Ltd. Compositions, Methods, and Kits for Treating Influenza Viral Infections
EP3558301A4 (en) * 2016-12-22 2020-07-29 MediciNova, Inc. METHOD FOR TREATING GLIOBLASTOMA MULTIFORME WITH IBUDILAST
CA3023014C (en) * 2017-11-06 2023-09-26 Stalicla Sa Pharmaceutical composition for treatment of autism
CA3090887A1 (en) * 2018-02-12 2019-08-15 Medicinova, Inc. Methods of suppressing myeloid-derived suppressor cells in patients

Similar Documents

Publication Publication Date Title
JP2020033360A5 (cg-RX-API-DMAC7.html)
JP2014515373A5 (cg-RX-API-DMAC7.html)
US20230364044A1 (en) Methods of Treating or Preventing Acute Respiratory Distress Syndrome
BR112012015202B1 (pt) uso de iota- e/ou kappa-carragenano junto com um inibidor da neuraminidase, e, composição farmacêutica
ES2906551T3 (es) Uso de hidrocloruro de landiolol en el tratamiento a largo plazo de taquiarritmias
CN1379665A (zh) 通过吸入法送递联苯胺前列腺素的方法
JP2023523557A5 (cg-RX-API-DMAC7.html)
US12514830B2 (en) Idebenone for the treatment of Acute Respiratory Distress Syndrome (ARDS) in patients diagnosed with a coronavirus infection
JP2024540439A5 (cg-RX-API-DMAC7.html)
JP2024531799A5 (cg-RX-API-DMAC7.html)
JP2022177119A5 (cg-RX-API-DMAC7.html)
EP4142731A1 (en) Treatment of pulmonary complications of coronavirus infections
MX2012005551A (es) Tratamiento de infecciones microbianas.
ES2894330T3 (es) Acido acetilsalicílico para uso en el tratamiento de la influenza de moderada a grave
CN113694177B (zh) 器官损伤的预防和治疗
US20230346793A1 (en) Compositions and Methods for Treating SARS-CoV-2
RU2018144248A (ru) Схемы дозирования вортиоксетина для быстрого появления антидепрессивного эффекта
JP2013523844A5 (cg-RX-API-DMAC7.html)
WO2021207489A1 (en) Methods and pharmaceutical compositions to treat pulmonary inflammation in infected patients
JP2023518430A5 (cg-RX-API-DMAC7.html)
JP2022542305A5 (cg-RX-API-DMAC7.html)
RU2830584C1 (ru) Ингибиторы cxcl8 для применения в лечении covid-19
JP2019533018A5 (cg-RX-API-DMAC7.html)
EP4008325A1 (en) Cxcl8 inhibitors for use in the treatment of covid-19
US20230141355A1 (en) Cxcl8 inhibitors for use in the treatment of covid-19